Medical Oncology Hematology Consultants — Newark, Delaware

Public research footprint of Medical Oncology Hematology Consultants, compiled from the ClinicalTrials.gov public registry.

326

Registered studies

208

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma · Recurrent Melanoma · Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Metastatic Melanoma

Recently updated registry entries

NCT02196181 — Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer… (Active Not Recruiting)
NCT03775265 — Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle… (Active Not Recruiting)
NCT02506153 — Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Medical Oncology Hematology Consultants?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.